Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis - PubMed
5 hours ago
- #weight-loss
- #pharmacotherapy
- #obesity
- The study analyzed the relationship between early rapid weight loss and the efficacy and safety of tirzepatide vs. semaglutide in obesity management.
- Rapid responders were defined as participants achieving ≥15% body weight reduction by Week 24, with 32.3% of participants meeting this criterion (44% on tirzepatide, 21% on semaglutide).
- Rapid responders had higher proportions of achieving body weight reduction thresholds by Week 72 compared to non-rapid responders.
- Safety profiles for tirzepatide and semaglutide were similar between rapid and non-rapid responders, though rapid responders reported more gastrointestinal/hepatobiliary adverse events.
- Study treatment completion rates were similar between rapid and non-rapid responders for both medications.
- Tirzepatide-treated participants achieved higher body weight reduction thresholds compared to semaglutide in both responder groups.